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Slimmary 
A  previous report  showed that  the proliferative response of helper T  cells  to  class II major 
histocompatibility complex (MHC)-restricted antigens can be inhibited by analogues of the antigen, 
which act as T  cell receptor (TCR) antagonists.  Here we define and analyze peptide variants 
that  antagonize various functions of class I MHC-restricted cytotoxic T  lymphocyte (CTL) 
clones.  Of 64 variants at individual TCR contact sites  of the Kb-restricted octamer peptide 
ovalbumin257-264  (OVAp),  a very high proportion  (40%)  antagonized lysis by three OVAp- 
specific CTL clones. This effect was highly clone specific, since many antagonists for one T cell 
clone have differential effects on another. We show that this inhibition of CTL function is not 
a result of T ceU-T cell interaction, precluding veto-like phenomena as a mechanism for antagonism. 
Moreover, we present evidence for direct interaction between the TCR and antagonist-MHC 
complexes. In further analysis of the T  cell response, we found that serine esterase release and 
cytokine production are susceptible to TCR antagonism similarly to lysis. Ca  2+ flux, an early 
event in signaling, is also inhibited by antagonists but may be more resistant to the antagonist 
effect than downstream responses. 
F 
or mature T cells, stimulation of the TCK by an appro- 
priate peptide-MHC complex on an APC usually results 
in activation. However, recent data have demonstrated that 
certain variants of the antigenic peptide can inhibit the prolifer- 
ative response of helper T cells to antigen (1). Those experi- 
ments showed that this effect was not due to blockade of 
the restricting MHC molecule by the variant peptide, a form 
of peptide inhibition that has been well described (2-4), and 
indicated that the peptide variants acted as TCR antagonists, 
i.e., interacted with the TCR without inducing a signal (1). 
Analogous results have been obtained by others showing that 
differential T cell signals may be obtained with mutated an- 
tigenic peptides (5). Together these data indicate that TCRs 
make a novel interaction with antagonist peptide-MHC com- 
plexes,  which does not produce a typical signal. However, 
it is still unclear exactly what quantitative and qualitative differ- 
ences distinguish the TCR interaction with agonist versus 
antagonist peptides. Furthermore, what signals  (if any) re- 
sult from antagonist-MHC interaction and how these trans- 
late into the T cell inhibition observed is unknown. Previous 
reports have focused on helper cell jproliferation  (1, 5), but 
other steps in the signaling pathway nave not so far been ana- 
lyzed for their sensitivity to antagonism. 
We wished to investigate the nature of the TCR. interac- 
tion with antagonist peptides and to explore the mechanism 
by which TCR antagonism inhibits T  cell function. This 
report describes a large panel of TCR antagonists that in- 
hibit CTL lysis in a clone-specific manner. Sensitivity to an- 
tagonist interaction was also analyzed for other T  cell re- 
sponses  ranging from immediate to late activation events. 
Materials and Methods 
Cell Lines.  The ovalbumin2s7-2~  (OVAp)l-specific,  Kb-restricted 
CTL clones B3 and GA4 were derived and maintained as described 
(6) with weekly restimulation on the OVA-transfected  EL4 clone 
E.G7 (7) in the presence of 5% rat Con A supernatant.  TG-1 is 
a CTL clone derived from an OVAp/Kb-specific TCR transgenic 
mouse, which will be fully described elsewhere (F. IL. Carbone, 
unpublished data). It uses the TCK Va5 chain expressed by B3 
and a TCR V~2 chain that pairs naturally with this ~ chain but 
does not derive from B3 (J. Kelley and F. R. Carbone, unpublished 
data). The VSV-1 CTL are specific for the VSV nucleoprotein 
(VSV-N), restricted by K  b, and were derived and maintained as de- 
scribed (8). EL4 was maintained in RPM11640 supplemented with 
10% heat-inactivated  FCS, 2 mM t-glutamine, and antibiotics (RP10 
medium). The cell line FDC.P1 (9), a kind gift of Dr. Kevin Leslie 
1  Abbreviations used in this.paper:  OVAp, ovalbumin2s7_264;  VSV-N, vesicular 
stomatitis virus nucleoprotein. 
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strongly to IL-3 and GM-CSF (10). This line was maintained in 
Ib3-containing tissue  culture supernatants. 
Pelotides.  tingle amino acid variants of OVAp were initially made 
using  the Multipin  Synthesis  System  (11) (Chiton Mimotopes, 
Clayton, Australia).  Some peptides were prepared using f-moc syn- 
thesis  on a peptide synthesizer (430A;  Applied Biosystems,  Inc., 
Foster City, CA) at the Howard Hughes Chemical Synthesis  fa- 
cility  (University  of Washington)  or  on  a  RAMPS apparatus 
(DuPont-NEN Products, Boston, MA), and were purified by HPLC 
(Waters,  Milford, MA). Peptide concentrations were determined 
using the BCA assay (Pierce Chemical Co.,  Rockford, IL). 
Prepulse CTL Lysis Assays.  EL4 cells were labeled with SlCr- 
sodium chromate in RP10 for 1 h at 37~  at a concentration of 
5  x  106/ml. A suboptimal concentration of OVAp or VSV-N pep- 
tide (3-10 pM) was introduced for the duration of the labeling. 
The cells were then washed three times in RP10. The cells were 
resuspended to 2  x  10  s cells/ml, and 50 #1 (104 cells) was trans- 
ferred to a well of a round-bottomed 96-well plate containing 50 
#1 PBS or the test peptide diluted in PBS. In the initial screening 
the OVAp variant peptides were tested at ',~4/zM concentration. 
After incubation for 30 min at 37~  CTL were added in 100 #1 
RP10 to give an E/T ratio of 3:1. The assay plate was maintained 
in a 37~  incubator with 5% CO2 for 2.5-5 h, after which the 
plate was centrifuged and 100/~1 of the supernatant removed and 
counted. 
Percent specific lysis was determined as follows: percent specific 
lysis =  100x  [(experimental release  -  spontaneous release)/(de- 
tergent release  -  spontaneous release)]. Spontaneous release was 
<20% in all assays described. Percentage inhibition oflysis was cal- 
culated as follows: percent inhibition  =  100x [(A  -  B)/(A)],  where 
A  is the percent specific lysis in the absence of inhibitor, and B 
is the percent lysis in its presence. 
In experiments to determine whether the variant peptides were 
agonists, the labeling was performed in the absence of added OVAp 
peptide.  In some experiments, the OVAp-pulsed saCr-labeled EL4 
cells were washed three times and then pulsed with a second pep- 
tide for 1 h at 37~  and at 5  x  106 cells/ml in RP10. After a fur- 
ther three washes,  the cells were diluted and incubated with the 
CTL as described  above. 
Cold Target Competition Assay.  Hot targets were EL4, slCr la- 
beled and prepulsed with 3 pM OVAp as described above. Cold 
targets were unlabeled EL4, unpulsed or pulsed with OVAp (10 
nM) or the D7 peptide (5 or 50 ttM) as indicated. All target cells 
were washed three times in RP10 before addition to the assay. Hot 
targets  were introduced at  10  4  cells/well,  cold targets  at  2  x 
10S/well, and CTL were added to 3  x  104/well to give a total 
volume of 200 #1. The CTL assay was  then incubated and har- 
vested  as described above. 
Serine Esterase Assay.  EL4 cells were irradiated (20,000 tad) and 
then coated at the indicated concentrations of OVAp  for 1 h at 
37~  The cells were washed three times and then incubated in 
RP10 media alone or with 1 #M D7 for a further 1 h at 37~ 
After three washes, 2  x  10  s pulsed EL4 in 100 #1 were added to 
wells of a 96-well flat-bottomext plate containing B3 CTL (10s/100 
/xl). Spontaneous release was measured from B3 cells incubated alone, 
while total serine esterase activity was determined from B3 cells 
treated with 0.5% NP-40 at the start of the assay. The plate was 
placed in a 37~  incubator with 5% CO2 for 3-12 h. The super- 
natant was then assayed for BLT serine esterase activity, as described 
(12, 13). Briefly, the plate was centrifuged (5 min) and 20 gl of 
supernatant removed and mixed with 180 ttl of reaction buffer (2 
￿  10 -4 M N~-benzyloxycarbonyl-r-lysine  thiobenzyl ester and 1.1 
￿  10 -4 M 5,  5'-dithio-bis-[2-nitrobenzoic acid] in PBS, pH 7.4 
[Sigma Chemical Co., St. Louis, MO]). After incubation at room 
temperature for 1 h, the absorbance at 405 nm was measured in 
an ELISA plate reader (EL312e microplate reader; Bio-Tek Instru- 
ments,  Winooski, VT). Data are expressed  as percentage serine 
esterase release following the formula used for CTL lysis assays. 
IL3 Production.  Culture conditions for this assay were iden- 
tical to those used for the serine esterase assay, except that half the 
number of EL4 cells were used. After a 24-h incubation the plate 
was centrifuged briefly and 100 #1 of supernatant was removed and 
diluted serially. The GM-CSF/IL-3-dependent line FDC.P1 (9, 10) 
was washed in RP10 and added to the diluted supernatants at 2 
￿  104 cells/well,  giving a final volume of 200/zl. After 48 h, 0.5 
/zCi of [3H]thymidine was added, the cultures were harvested  16 h 
later,  and the 3H incorporation was measured. 
Ca  2+ Flux Assay.  EL4 cells were pulsed with OVAp at the in- 
dicated concentrations in ILP3 (as for RP10 but with 3%  FCS) 
for 45 min at 37~  washed two times,  and then incubated for 
a further 45 min in RP3 with or without 1/zM D7 peptide. After 
three washes,  the EL4 cells were resuspended in ,,o100/xl RP3. 
B3 CTL were loaded for 90 rain in Indo-1 (~25 #g/ml; Molecular 
Probes,  Inc., Eugene, OR) at 37~  in RP3, washed twice, and 
resuspended at 104/mI in RP3. After warming to 37~  10  e CTL 
were mixed with 3  x  104 EL4 cells in a total volume of 1.1 ml. 
It was found that under these conditions calcium flux in the CTL 
was undetectable until the cells were centrifuged together (data 
not shown). The cells were analyzed on a FACStar Plus  |  (Becton 
Dickinson & Co., Mountain View, CA) using Becton Dickinson 
software.  The B3 cells were live gated on the basis of their Indo-1 
loading. A baseline measurement for the ratio of calcium bound/un- 
bound Indo (expressed as violet/blue ratio) in the B3 cells was then 
monitored for 1 min. The sample was then removed, and the cells 
were pelleted together briefly (~10 s) in a microfuge. The cells 
were immediately resuspended and analyzed on the FACStar Plus  | 
over ~6 min. The data were reanalyzed using the software Repro- 
man (D. Coder, Cell Analysis Facility, Department of Immunology, 
University of Washington) and M-Time (14). An analysis gate using 
forward and side scatter to exclude dead cells and tumor cells was 
applied. 
Results 
Variants at TCR  Contact Sites of an Antigenk PeFtide Are 
Clone-Specific Antagonists.for  CTL Lysis.  TCR antagonists 
have so far only been described for the proliferative function 
of class  II-restricted  CD4 +  T  cells  (1,  5).  Therefore,  we 
wished to determine first whether the effects of antagonists 
could be extended to class I-restricted CTL, using target cell 
lysis  as  an  assay.  Previously we described the  fine antigen 
specificity of two CTL clones, B3 and GA4, specific for the 
OVA peptide, OVAp (sequence SIINFEKL), in the context 
of K b (6,  15,  16).  In that  analysis we proposed TCR con- 
tact residues  at positions  4,  6,  and  7 of the peptide,  with 
position 2 contributing weakly to T  cell recognition (16). 
These assignments correspond with the TCR contacts pre- 
dicted from the crystal structure of OVAp/K  b (M.  Matsu- 
mura and I. Wilson, personal communications). Accordingly, 
we generated 64 single amino acid variants of OVAp at these 
four positions  (all 20 amino  acids,  except C,  M,  and W). 
These peptides were tested for their capacity to inhibit CTL 
lysis in an assay designed to distinguish  TCR antagonism 
from competition for MHC binding. This involves prepulsing 
the target cells with a suboptimal dose of OVAp peptide be- 
fore incubating them with the variant peptide and CTL. Such 
an assay is represented in Fig.  1, showing the effect of three 
OVAp variants on lysis by B3,  GA4,  and CTL specific for 
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RGYVYQGL) (8, 17). Another peptide is also described in 
this figure, V-OVA, which is comprised of three dominant 
TCR contacts from the OVAp peptide (positions 4, 6, and 
7) incorporated into the VSV-N peptide. The OVAp variant 
D7 is a potent antagonist  for both OVAp/Kb-specific CTL 
clones. Other peptides showed differential effects on the two 
OVAp-specific CTL clones: the peptide L6 antagonizes the 
lysis mediated by B3 but does not affect GA4. Conversely, 
V-OVA inhibits  cytotoxicity by GA4 but not B3 (Fig.  1). 
Some peptides antagonized lysis by both CTL clones but with 
different efficiency, e.g., the peptide A4 is a strong antagonist 
of GA4 and a weaker antagonist  of B3. These antagonists 
were all active at very low concentrations (100 pM to 1 riM). 
The existence of peptides that are antagonists for one OVAp/ 
Kb-specific  CTL but not the other demonstrates these vari- 
ants do not  simply catalyze displacement  of bound OVAp 
peptide  from the K b groove.  This  conclusion  is  also sup- 
ported by the inability of an unrelated K b binding peptide 
(e.g., VSV-N) to decrease B3- or GA4-mediated lysis in these 
assays (data not  shown). 
In contrast  to the dramatic effects on killing by B3 and 
GA4, none of the OVAp variants significantly inhibited lysis 
by the VSV/Kb-specific  CTL, VSV-1 (Fig.  1 c). On the other 
hand,  all the variants bound K b molecules similarly to the 
OVAp peptide, as measured by a K b stabilization on the mu- 
tant  cell RMA-S (16,  18,  19,  and data not  shown).  Taken 
together,  these results suggest that the OVAp-specific CTL 
inhibition  was not  some form of MHC blockade or CTL 
toxicity. 
In this way we analyzed the panel of OVAp variants for 
their capacity to cause a significant  reduction in the lysis medi- 
ated by B3, GA4, and a third CTL clone, TG-1. The clone 
TG-1  derives  from  a  OVAp/Kb-specific  TCR  transgenic 
mouse. The transgenes it expresses are the TCR 3 chain from 
B3,  and a TCR ot chain  that  is unrelated  to that  used by 
B3 (15,  and F. R. Carbone,  unpublished data).  The results 
of this analysis  are listed in Table 1.  Of 65 variants  tested, 
26 (40%) were potent  antagonists  for one or more of the 
three CTL clones tested. Table I also describes the properties 
of these variants as antigens (agonists) for CTL lysis,  since 
several peptides were agonists for one clone while antago- 
nists for another.  Some peptides were agonists at high con- 
centrations and potent antagonists  for the same clone at greater 
dilutions. These are identified as scoring both as agonist and 
antagonist.  This result suggests that  Table  1 probably un- 
derestimates the true number of antagonist OVAp variants, 
since most variants were initially tested at a single concentra- 
tion (~4 #M, and hence agonists at this dose may be antag- 
onists  at  other concentrations. 
The majority of antagonists were found in variants at po- 
sitions 4, 6, and 7, which we had previously shown to be 
critical TCR contacts (16). A very large proportion (13/16) 
of position 4 variants were antagonists. In contrast, only one 
variant at position 2 was a strong antagonist for one of the 
CTL clones, B3. In line with this, we had previously shown 
that  alanine  substitution  at position 2 affected recognition 
by B3 but not by GA4 (16). Thus, the same positions of the 
peptide that  are important  for antigen  recognition  are in- 
volved in antagonist  peptide recognition.  In keeping with 
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Figure  1.  Variants  of the OVAp peptide are clone-specific  antagonists 
for CTL lysis. SlCr-labeled EL4 cells were prepulsed with 3 pM OVAp 
(a and b) or 3 pM VSV-Ns2-59  (c). The target cells were incubated with 
the indicated concentration of OVAp variant peptides. The following  CTL 
were then added: (a) B3, (b) GA4, and (c) VSV-1. Lysis  was determined 
2.5--4 h later. Specific  lysis  by all CTL in the absence  of  added OVAp  variant 
peptides was 25-30%. Data are shown as percent inhibition of this lysis, 
calculated as described  in Materials and Methods. The sequences of the 
OVAl> variants named are given in Table 1. 
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Residues changed  from 
OVAzsT-264  B3  GA4  TG-1 
Peptide  S  I  I  N  F  E  K  L  Agonist  Antagonist  Agonist  Antagonist  Agonist  Antagonist 
F2  ￿9  F  ￿9  ￿9  ￿9  ￿9  ￿9  ￿9  -  ++  ++  +  ++  - 
A4  ￿9  ￿9  ￿9  A  ￿9  ￿9  ￿9  ￿9  -  +  +  ++  +  +  + 
D4  D  -  ++  ++  +  -  ++ 
E4  E  .....  +  + 
F4  F  -  -  -  ++  +  ++ 
G4  G  -  ++  -  ++  ++  ++ 
14  I  -  +  -  ++  +  ++ 
L4  L  -  ++  -  ++  ++  ++ 
Q4  Q  -  +  -  +  +  +  +  - 
R4  R  -  -  +  ++  -  +  + 
$4  S  +  ++  -  ++  +  ++ 
T4  T  -  ++  -  ++  ++  - 
V4  V  -  +  -  ++  ++  + 
Y4  Y  +  -  -  ++  ++  ++ 
F6  ￿9  ￿9  ￿9  ￿9  ￿9  P  ￿9  ￿9  ++  +  +  -  -  ++ 
I6  I  -  ++  +  -  -  ++ 
L6  L  +  ++  -  -  ++  ++ 
P6  P  +  ++  ++  -  +  ++ 
V6  V  -  ++  -  +  -  ++ 
Y6  Y  ++  +  +  -  +  ++ 
97  ￿9  ￿9  ￿9  ￿9  ￿9  ￿9  D  ￿9  -  ++  -  ++  +  ++ 
E7  E  ++  +  -  ++  +  ++ 
I7  I  +  ++  ++  ++  ++  ++ 
L7  L  +  ++  ++  +  ++  ++ 
P7  P  -  ++  ++  -  -  ++ 
V-OVA  R  G  Y  ￿9  Y  ￿9  ￿9  ￿9  -  -  +  +  +  -  +  + 
Peptide names follow from the amino acid substitutions that distinguish them from OVAp, the sequence of which is given. The maximum capacity 
of these peptides to agonize or antagonize CTL-mediated lysis over a large concentration range (from ~1/~M to "~100 pM) is summarized. For 
agonists:  -,  <5% specific lysis;  +, 5-30%; and +  +, >30%. As antagonists:  -,  <20% inhibition oflysis;  +, 20-50%; and  +  +, >50% inhibition. 
this conclusion, there is pronounced clone specificity in sus- 
ceptibility to antagonism. Indeed, when the degree of agonism 
and/or antagonism was evaluated (Table 1), none of the OVAp 
variants acted in the same way for all three CTL clones. The 
B3 and GA4 clones,  which use different TCR Va and V~ 
segments (J. Kelley and F. R. Carbone,  unpublished data), 
shared the same pattern of antagonism for only 6 of the 26 
peptides  identified.  Furthermore,  the B3 and TG-1 clones, 
which have identical 13 chains, also overlap for only 6 of 26 
peptides. Indeed, some peptides were antagonists for one clone 
while acting as agonists for another (Table 1). Together these 
data indicate there is TCR fine specificity for the interaction 
with antagonist peptides, probably involving similar TCR 
elements  as  are  used  for  antigen  recognition. 
The Effect of Antagonists Is Not Mediated by CTL-CTL In- 
teraction.  In the assays described above, the antagonist pep- 
tides were present throughout  the course of the CTL  lysis 
assay.  Since the CTL  themselves express the appropriate re- 
striction dement  (Kb), it was possible that the decreased lysis 
observed arose from CTL-CTL  interaction, leading to an in- 
hibition of function.  Such effects have been reported previ- 
ously induding  experiments using OVAp-specific CTL  clones 
(20--22). In particular there is precedent for inhibition of CTL 
activation by interaction with  CD8-bearing  target cells (23). 
To test for this directly, we pulsed the antagonist peptide D7 
onto either the target cells or the CTL  before the assay. The 
data shown  in Fig.  2  clearly indicate that while coating the 
effector cells in a  high dose of the D7  peptide had no effect 
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with this peptide profoundly inhibited lysis. Since the same 
protocol was used for pulsing the D7 peptide on both target 
and CTL, the result is probably not due to antagonist carry- 
over into the assay. This phenomenon was CTL clone specific 
since when the peptide V-OVA was used in place of D7 to 
coat target cells, lysis by GA4 but not B3 was inhibited (data 
not shown). These data argue that antagonism involves rec- 
ognition of antagonist peptide expressed on the APC rather 
than through CTL-CTL interaction. 
Evidence for Direct TCR Recognition of Antagonist-MHC 
Complexes.  Among the OVAp variants, we found some that 
actedas both agonist and antagonist for the same clone. This 
is demonstrated in Fig. 3 with the peptide P6. An agonist 
for the clone GA4, this peptide acts as both a weak agonist 
and an antagonist for B3. Thus at the same concentration, 
this peptide is capable of weakly stimulating B3 while an- 
tagonizing a stronger response. Several other peptides with 
similar activities were identified. The agonist properties of 
the OVAp variants analyzed are therefore listed in Table 1. 
These properties are characteristic of partial agonist/antago- 
nists,  a class of ligand defined as having low efficacy, i.e., 
producing a weak maximal response (24).  Thus these data 
indicate that  the TCR interacts with  the partial agonist/ 
antagonist producing a suboptimal lytic signal. Other vari- 
ants were strict antagonists; i.e., they were unable to stimu- 
late CTL lysis at any concentration tested. We tested TCR 
recognition of one of these peptides (D7) using a cold target 
competition assay (see Materials and Methods). As shown 
in Fig. 4, lysis of SlCr-labeled target cells by B3 was not in- 
hibited by unlabeled EL4 but was efficiently inhibited by EL4 
coated in OVAp peptide. When D7 peptide-coated EL4 cells 
were used as competitors, lysis was reduced by "~50%. The 
data are presented for cold targets pulsed with 5 and 50/zM 
D7, which gave essentially identical results. A similar degree 
of inhibition was observed when the cold targets were pulsed 
at 1/~M D7 and with cold/hot target ratios as low as 7.5:1 
(data not shown). The effect titrated out at lower cold/hot 
25 t 
20- 
.2 
.~  lS' 
r 
10. 
O. 
EL4/OVA pulsed with D7  +  +  +  + 
B3 pulled with D7  +  +  +  + 
D7 in assay  +  +  +  + 
Figure 2.  TCR. antagonism is not mediated through T cell-T cell con- 
tact. A prepulse lysis assay was performed as described in Fig. 1, except 
that either the OVAp-coated EL4 target cells or the B3 effector cells were 
then pulsed with 5/~M of the D7 antagonist peptide for 1 h before the 
assay, as indicated.  In some cases, free D7 peptide (100 nM) was added 
directly  to the assay, as indicated. 
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Figure 3.  The P6 peptide is a partial agonist/antagonist for the B3 CTL 
and is an agonist for GA4. The CTL clones B3 and GA4 were tested for 
their response to the peptide P6 as an antagonist (a) or an agonist  (b). 
EL4 were prepulsed with 3 pM OVAp (a) or media alone (b) before incu- 
bation with the indicated concentrations  of P6. The lysis by B3 (O) and 
GA4 (O) is indicated by circles. Lysis in the absence of added 1)6 peptide 
is represented in a by triangles. 
ratios 44:1) (data not shown), which explains why no inhibi- 
tion of CTL lysis was observed in Fig. 3 (the B3 CTL them- 
selves could act as cold targets, but in those experiments they 
are at an effective cold/hot ratio of only 3:1). These data sug- 
gest that there is a direct interaction between the B3 TCR 
and the D7 peptide-K  b complex, although this interaction 
does not lead to lysis of the target cell. 
Serine Esterase  Release, Cytokine Production,  and Cakium Flux 
Are All Susceptible to TCR Antagonism, but Differ in the De- 
gree of  Sensitivity.  The assays described so far assess the effect 
of antagonists on a single aspect of CTL activation, i.e., lysis. 
Since the mechanism of TCR antagonism is unknown, it 
is valuable to determine which events in the T cell signaling 
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Figure 4.  Cold target competition assay demonstrates  a weak direct 
interaction  between TCR and antagonist-MHC complex.  51Cr-1abeled 
EL4 cells were prepulsed with 3 pM OVAp. Cold targets were EL4 calls 
that were pulsed with OVAp or D7 peptides as indicated.  The effect of 
D7 peptide added directly to the assay (100 nM) is identified (+  D7 pep- 
tide). The hot/cold target ratio was 1:20 and the effector/hot target ratio 
was 3:1. 
cascade are affected by antagonists  and which are not.  We 
first tested another parameter that may be related to the cyto- 
toxic function,  serine esterase release  (12,  13). As shown in 
Fig.  5 a,  the D7 peptide itself did not stimulate serine es- 
terase release, but it did drastically inhibit the release in re- 
sponse to various doses of OVAp peptide coated onto stimu- 
lator cells. This effect was consistent over a long time course: 
serine esterase  assays from 3 to 24 h  after initiation  of the 
culture showed similar effects (data not shown). We also as- 
sayed the production of lymphokines after CTL activation. 
Production of both GM-CSF and IL-3 has been reported for 
CD8 + cells (10, 25, 26). Hence we tested supernatants from 
CTL cultures 24 h after stimulation for their capacity to stimu- 
late the FDC.P1 cell line,  which responds strongly to both 
cytokines (9, 10). A similar antigen sensitivity was observed 
for this function as for lysis and serine esterase  release (Fig. 
5 b). Profound inhibition of cytokine production was observed 
when stimulators were pulsed with antagonist peptides.  Thus 
the inhibitory effect of the antagonists  is long lasting  and 
affects several  aspects  of the  T  cell  response.  Both  assays 
depicted in Fig.  5 also show that the effects of the antago- 
nists are, to some degree,  surmountable through using higher 
doses of antigen in the prepulse (compare inhibition at 3 pM 
OVAp with that  at 9 pM).  Lysis of target cells is also sur- 
mountable in this way (data not  shown). 
A very early event in T  cell activation is mobilization of 
intracellular  calcium. We tested the effect of TCR antago- 
nists on this response.  The assay shown in Fig.  6 a  shows 
a strong  Ca  2+  flux response of the B3 CTL clone to EL4 
cells coated in a high concentration of OVAp (1 #M). Similar 
responses were observed when  anti-CD3  crosslinking  was 
used to stimulate the B3 cells (data not shown). In contrast, 
no  Ca  2+  response  was  stimulated  by  EL4  alone  or  EL4 
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Figure 5.  Serine esterase release and GM-CSF/Ib3 production are sus- 
ceptible to TCR antagonism.  (a) B3 cells were cultured with irradiated 
EL4 stimulator cells pulsed with the indicated  concentration  of OVAp 
peptide. Some stimulators were pulsed for a second time with D7 peptide 
(1/tM), as indicated.  Serine esterase release was determined  after  12 h. 
(b) Culture supernatants  after CTL stimulation  with the indicated stimu- 
lator cells were diluted  1:5 and assayed for stimulation  of FDC.P1  cell 
proliferation,  measured  by  [3H]thymidine  incorporation.  This  cell re- 
sponds to both GM-CSF and IL3 (10). Both assays were conducted in tripli- 
cate and error bars show the standard  deviations. 
coated in 1/~M D7 (Fig.  6 a). As was the case in the other 
assays described, a suboptimal calcium flux response of B3 
was observed when stimulators were pulsed in picomolar con- 
centrations  of OVAp.  We therefore assayed calcium flux in 
response to EL4 cells coated with various low doses of OVAp, 
with or without subsequent pulsing with the D7 antagonist 
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Figure 6.  Ca  2+ flux  is inhibited  by antagonist  peptide interaction. The 
calcium flux  response of B3 cells was measured. The figures  show a base- 
line calcium measurement  (indicated  by the Indo-1 violet/blue  ratio) for 
1 rain, after  which the cells  were  briefly  centrifuged  together,  resuspended, 
and reanalyzed  for at least 6 rain. (a) B3 responses are shown to the fol- 
lowing stimulator  cells: EL4 cells (lower solid line), EL4 pulsed  with 1/~M 
OVAp peptide (upper solid line),  1/zM D7 peptide (dashed line),  20 pM 
OVAp (dotted-dashed line), or 20 pM OVAp followed  by 1/~M D7 (dotted 
line).  (b) Responses to EL4 cells pulsed with 10 pM OVAp (upper solid 
line), 5 pM OVAp (dashed line), 10 pM OVAp followed  by a ~M D7 (dotted 
line), and 5 pM OVAp then 1/tM D7 (dotted-dashed line). The lower solid 
line shows  the response to EL4 cells  coated  in 1/~M D7 peptide. (c) Serine 
esterase release from the cells assayed  for calcium flux. The experiment 
was performed  as described in Fig. 5 a, except that serine esterase release 
was assayed  after 3 li. The percent specific release shown is the average 
for duplicate cultures that differed  by <12%. 
peptide. Immediately after the flux assay, the remaining cells 
were incubated for 3 h and serine esterase release was deter- 
mined, so that this aspect of activation could be directly com- 
pared to the flux response. The calcium flux response to EL4 
cells coated at 20 pM OVAp is shown in Fig. 6 a. This re- 
sponse was not affected when D7 was pulsed onto the stimu- 
lator cells (Fig. 6 a). In contrast, the serine esterase response 
of these same cells was clearly inhibited by D7 pulsing (Fig. 
6 c), indicating a differential sensitivity between these two 
responses. Antagonism of the calcium flux response was ob- 
served, however, when lower doses of antigen were used for 
pulsing. OVAp pulsing at doses of 10 and 5 pM leads to de- 
creased flux responses (Fig. 6 b) (note the reduced scale rela- 
tive to Fig. 6 a). Under these conditions, pulsing with the 
D7 peptide leads to strong inhibition of the calcium flux re- 
sponse (Fig.  6 b) and serine esterase response (Fig.  6 c). Yet 
here also, some difference was seen in the degree of  antagonism 
between the two assays: at 5-pM pulsing the serine esterase 
assay is almost fully inhibited (Fig. 6 c), whereas calcium flux 
is only reduced by '~60%  (Fig.  6 b). 
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Together, these data suggest that the effect of antagonist 
peptides is evident at the level of Ca  z+  flux, but that this 
event is more resistant to antagonism than downstream re- 
sponses. 
Discussion 
We demonstrate here the existence of TCR antagonist pep- 
tides affecting CTL  function. We generated a large panel of 
variants of the peptide OVAp that acted as antagonists for 
three OVAp/Kb-specific CTL  clones. Several aspects of these 
results are interesting. 
(a) The peptide residues identified as important for TCR 
recognition (positions 4, 6, and 7) were also the positions 
that yielded multiple antagonists, whereas substitutions at 
a position that was less important for TCR recognition (po- 
sition 2) produced only one potent antagonist peptide. This 
indicates that the recognition of antagonist peptide probably 
involves the same portions of the TCR as are used to recog- 
nize the antigenic peptide (16). (b) No simple chemical features unite the antagonist vari- 
ants at a certain position. Generally, aliphatic residues acted 
as antagonists for at least one CTL done, but occasional nega- 
tively charged and aromatic residues also emerged as potent 
antagonists, especially at position 4 (Table 1). One striking 
trend, however, was that negatively charged residues (Asp 
and Glu) at position 7 of OVAp were strong antagonists for 
GA4. In contrast, it has been demonstrated that among vari- 
ants at this position the best agonists have positively charged 
residues (His, Lys, or Arg) (15). In this case then, there may 
be charge interactions between the peptide and the TCR. 
and/or K b molecule that dictate whether the T  cell interac- 
tion will lead to stimulation or antagonism. However, the 
variants at position 4, which act as GA4 antagonists, are so 
varied that it seems most likely that the effect is due to a 
loss  of interaction with asparagine at this position,  rather 
than a novel interaction with the substituted amino acid. Our 
data thus do not support the contention by Alexander et al. 
(27) that antagonists arise primarily from conservative sub- 
stitutions  at TCR contacts. 
(c) Over one-third of the single amino acid OVAp variants 
tested were antagonists for one or another CTL done. Looking 
at position 4, this proportion rises to >80%  of tested vari- 
ants. Thus the frequency and diversity of antagonist variants 
are strikingly high. We also analyzed a peptide (V-OVA) that 
differs more extensively from OVAp. Although it shares only 
four of eight residues with OVAp,  this peptide is a potent 
antagonist for the clone GA4. Together, these results indi- 
cate that peptides that are quite distantly related to the an- 
tigen may be antagonists. This conclusion suggests that specific 
antagonists could be frequent among MHC binding peptides 
and hence may exist among naturally occurring self-peptides. 
Furthermore, the amounts of antagonist peptide needed for 
detection in our assays (20-200 fmol for several variants) in- 
dicate physiological levels of natural peptides (28, 29) could 
influence CTL function. Thus we propose to use the high 
sensitivity of our assays to search for such naturally occur- 
ring antagonist peptides. 
(d) All of the antagonists identified had differential effects 
on the three CTL clones tested. This ranged from opposites 
in stimulatory properties (agonist vs. antagonist) to more subtle 
differences in the degree of the T  cell response. This result 
has important ramifications on the potential use of antago- 
nists in inhibiting T  cell responses in vivo since it is clear, 
based on our observations, that a polyclonal T cell response 
will be difficult to antagonize. Indeed, we have observed such 
resistance to antagonism in the response of a bulk OVA/K  b- 
specific CTL line (our unpublished observations). On the other 
hand, T cell responses of less diversity, as have been reported 
in several cases (30-36),  may be very susceptible to antagonism. 
Another characteristic of TCR antagonists is that they in- 
hibit T cell function in MHC competition assays with greater 
efficiency than expected from their MHC binding capacity 
(1). In our system, MHC binding competition only causes 
inhibition of lysis when unrelated K b binding peptides are 
present at at least 1,000-fold higher concentration than tar- 
geting peptide (data not shown). However, lower doses of 
antagonist peptides are needed to show inhibition in this assay. 
Thus, variants A4 and P6 are equally effective in K b blockade 
for VSV-N52-59-specific CTL, but P6 is at least 10-fold more 
efficient than A4 in inhibition of B3 response to OVAp, cor- 
relating with their properties as B3  antagonists (data not 
shown). 
It was previously unclear what sort of interaction occurred 
between the TCR and the antagonist-MHC complex. In- 
deed, previous studies failed to detect any form ofT cell stim- 
ulation through antagonist-peptide interaction (1). We present 
two lines of evidence indicating direct TCR recognition of 
the antagonist complex. First we describe a large class of TCR 
partial agonist/antagonists. At particular concentrations some 
of these peptides are weak stimulators, but at the same time 
act as antagonists (see Fig. 3). Thus, there is clearly a specific 
TCR interaction involving peptides that act as antagonists. 
Second, we investigated the activity of a pure antagonist in 
cold target competition assays. The inhibition observed with 
antagonist peptide-coated cold target cells supports the idea 
that TCR-mediated engagement is occurring, effectively dis- 
tracting the CTL from lysing the OVAp-coated hot targets. 
It is not clear exactly why the inhibition was consistently 
low ('~50%),  despite titrations of antagonist peptide and 
cold/hot target ratios, but this result may indicate a weak 
TCR interaction with the antagonist-MHC. 
Taken together, these data can be interpreted as meaning 
there is  a low  affinity interaction between TCR  and  an- 
tagonist-MHC that is sufficient to occupy TCR but that falls 
short of stimulating the necessary numbers of TCR for trig- 
gering a response. This view was also concluded in a recent 
paper from Sette's group (27). However, an equally valid in- 
terpretation is that antagonism operates through a qualita- 
tive difference in the signal imparted through agonist vs. an- 
tagonist peptid~ This could be due to conformational changes 
induced in the TCR itself or result from differences in the 
activation of other costimulatory molecules or adhesion mol- 
ecules (37-39).  A few examples of differential signaling in- 
duced by variant antigens have been described (5,  40).  By 
this argument, the weak interaction between the T cell and 
antagonist-coated APC (this paper) would result from the 
lack of (conventional) T cell stimulation, since TCR activa- 
tion is associated with both enhanced T cell-APC conjuga- 
tion and potentiation of accessory molecule activity (37-39). 
In this scenario,  our data do not directly address the affinity 
between TCR and antagonist peptide. Direct measurements 
of the affinity of TClk for antagonist-MHC complexes (41, 
42) will thus be valuable in approaching this issue. However, 
our observations with partial agonist/antagonists can be in- 
terpreted as indirect support for a qualitative difference in 
the T cell response. For example, the response of B3 to high 
concentrations of the peptide P6 is not altered by the simul- 
taneous presence of a suboptimal dose of OVAp (Fig.  3, a 
vs. b). This indicates that the response to OVAp is fully an- 
tagonized at this concentration of P6 and that the weak agonist 
response seen is due entirely to inefficient signaling through 
P6 recognition. This scheme most easily fits in with a model 
in which efficient engagement of the TCR by P6 results in 
an inefficient signal for target cell lysis. 
We have begun an analysis of several T cell functions for 
their susceptibility to antagonism. The release of serine es- 
terase from cytotoxic granules, and the synthesis of GM-CSF 
and/or IL-3, were found to be antagonized in a similar way 
to that observed for CTL lysis. Also studied was the Ca  2  + 
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antagonist peptide, but was more resistant to antagonism than 
another parameter of activation, serine esterase release. The 
possibility that assay of calcium flux reflects a nonphysiolog- 
ical degree of stimulation is unlikely since the flux response 
and the other responses  studied showed remarkably similar 
antigen dose responses. Thus, these data indicate that sequential 
stages in the activation pathway may show a differential sen- 
sitivity to antagonist interactions. 
Last, it is interesting to note the possible relevance of an- 
tagonist peptides to T cell development. During positive se- 
lection, thymocytes interact with self-peptide-MHC com- 
plexes  on  epithelial  cells,  resulting  in  their  rescue  from 
programmed cell death (43-47). On the other hand, it is evi- 
dent that engagement with stimulatory antigen-MHC com- 
plex at this stage leads to T cell tolerance by deletion or anergy 
(46,  48).  Thus  the nature of the TCR-ligand interaction 
leading to positive selection is presently an unresolved paradox. 
However, the characteristics  of the positive selection interac- 
tion are strikingly similar to those we describe here for TCR 
antagonists: a clone-specific,  MHC-restricted TCR interac- 
tion evidently occurs (43-46) but does not appear to induce 
activation (47). In this paper we have described TCR antag- 
onists for the CTL clone TG-1, which derives from a TCR 
transgenic mouse strain (F. R. Carbone, unpublished data). 
Hence, we will use this system to assess the role of TCR 
antagonists in T  cell positive selection. 
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